Israeli generics giant Teva restructures into four geographic divisions

Israel-based Teva Pharmaceutical Industries, the global leader in generic medicines, revealed that it is reorganizing its corporate structure, dividing the company into four geographic divisions, rather than the current two part structure of the USA and the rest of the world.

Each will be responsible for sales of all of the company's products in its region, including Teva's own patented drugs, the multiple sclerosis treatment Copaxone (glatiramer acetate injection) and Azilect (rasagiline) for Parkinson's disease, reported the local Haaretz Newspaper.

The change also involved the resignation of Chaim Hurvitz, who is the son of Teva's former chairman, Eli Hurvitz, from his position as head of the company's international group, said the Haaretz.